Cam Gallagher - Feb 10, 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Director
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Cam S. Gallagher
Stock symbol
ZNTL
Transactions as of
Feb 10, 2022
Transactions value $
-$360,775
Form type
4
Date filed
2/14/2022, 08:09 PM
Previous filing
Feb 7, 2022
Next filing
Feb 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +8.2K +2.12% $0.00 395K Feb 10, 2022 Direct F1
transaction ZNTL Common Stock Award $0 +7.6K +1.92% $0.00 403K Feb 10, 2022 Direct F2
transaction ZNTL Common Stock Sale -$104K -2.08K -0.52% $50.16 401K Feb 14, 2022 Direct F3, F4
transaction ZNTL Common Stock Sale -$13.1K -259 -0.06% $50.75 401K Feb 14, 2022 Direct F3, F5
transaction ZNTL Common Stock Sale -$243K -4.85K -1.21% $50.17 396K Feb 14, 2022 Direct F6, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +19.2K $0.00 19.2K Feb 10, 2022 Common Stock 19.2K $52.61 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in full on the first anniversary of the grant date.
F3 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021.
F7 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.77 to $50.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.